GRIFOLS S A/S (NASDAQ:GRFS) Raised to “Buy” at Banco Sabadell

Banco Sabadell upgraded shares of GRIFOLS S A/S (NASDAQ:GRFS) from a sell rating to a buy rating in a report released on Monday morning, The Fly reports.

Other equities research analysts have also issued reports about the stock. BidaskClub upgraded shares of GRIFOLS S A/S from a sell rating to a hold rating in a report on Wednesday, December 4th. Berenberg Bank upgraded shares of GRIFOLS S A/S to a buy rating in a report on Wednesday, October 30th. Zacks Investment Research lowered shares of GRIFOLS S A/S from a hold rating to a sell rating in a report on Friday, December 6th. ValuEngine upgraded shares of GRIFOLS S A/S from a sell rating to a hold rating in a report on Wednesday, October 2nd. Finally, Santander upgraded shares of GRIFOLS S A/S from a hold rating to a buy rating in a report on Monday, October 28th. Two research analysts have rated the stock with a sell rating, two have assigned a hold rating and four have assigned a buy rating to the company’s stock. The company has a consensus rating of Hold and an average price target of $20.75.

Shares of GRFS opened at $22.68 on Monday. GRIFOLS S A/S has a twelve month low of $17.42 and a twelve month high of $23.60. The firm’s fifty day simple moving average is $22.02 and its 200-day simple moving average is $21.03. The firm has a market capitalization of $15.56 billion, a price-to-earnings ratio of 20.39, a PEG ratio of 1.40 and a beta of 1.06. The company has a current ratio of 2.62, a quick ratio of 0.96 and a debt-to-equity ratio of 1.30.

GRIFOLS S A/S (NASDAQ:GRFS) last announced its quarterly earnings data on Tuesday, October 29th. The biotechnology company reported $0.28 earnings per share for the quarter, missing the Zacks’ consensus estimate of $0.31 by ($0.03). GRIFOLS S A/S had a net margin of 11.12% and a return on equity of 13.58%. The firm had revenue of $1.46 billion during the quarter, compared to analyst estimates of $1.39 billion. On average, analysts predict that GRIFOLS S A/S will post 1.16 earnings per share for the current fiscal year.

The business also recently declared a semi-annual dividend, which was paid on Wednesday, December 11th. Investors of record on Tuesday, December 3rd were paid a dividend of $0.169 per share. This is a positive change from GRIFOLS S A/S’s previous semi-annual dividend of $0.15. This represents a yield of 1.3%. The ex-dividend date was Monday, December 2nd. GRIFOLS S A/S’s dividend payout ratio (DPR) is currently 29.06%.

Large investors have recently made changes to their positions in the stock. Atria Investments LLC raised its stake in GRIFOLS S A/S by 89.2% during the 2nd quarter. Atria Investments LLC now owns 38,413 shares of the biotechnology company’s stock worth $1,492,000 after acquiring an additional 18,114 shares in the last quarter. Point72 Asset Management L.P. acquired a new stake in GRIFOLS S A/S during the 3rd quarter worth $14,664,000. Millennium Management LLC raised its stake in GRIFOLS S A/S by 611.4% during the 3rd quarter. Millennium Management LLC now owns 2,005,152 shares of the biotechnology company’s stock worth $40,183,000 after acquiring an additional 1,723,283 shares in the last quarter. JPMorgan Chase & Co. raised its stake in GRIFOLS S A/S by 3.7% during the 2nd quarter. JPMorgan Chase & Co. now owns 1,615,633 shares of the biotechnology company’s stock worth $33,233,000 after acquiring an additional 57,155 shares in the last quarter. Finally, Wells Fargo & Company MN raised its stake in GRIFOLS S A/S by 2.0% during the 2nd quarter. Wells Fargo & Company MN now owns 226,399 shares of the biotechnology company’s stock worth $4,777,000 after acquiring an additional 4,414 shares in the last quarter. Hedge funds and other institutional investors own 18.18% of the company’s stock.

About GRIFOLS S A/S

Grifols, SA, a specialty pharmaceutical company, develops, manufactures, and distributes a range of biological medicines on plasma derived proteins worldwide. The company operates through five segments: Bioscience, Diagnostic, Hospital, Bio Supplies, and Others. The Bioscience segment manufactures plasma derivatives for therapeutic use; and sells and distributes end products.

See Also: What is the Book Value of a Share?

The Fly

Analyst Recommendations for GRIFOLS S A/S (NASDAQ:GRFS)

Receive News & Ratings for GRIFOLS S A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GRIFOLS S A/S and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit